# Aju IB Investment

> Aju IB Investment is a VC fund backing Biotechnology and Health Care. See 160 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Yeoksamdong, South Korea
- Total investments: 160
- Last investment: Jun 2026
- Lead investor: 7%
- Last fund: Jun 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aju-ib-investment/
- Website: http://www.ajuib.co.kr

Aju IB Investment is a venture capital firm that offers SMEs with investments and consulting services.Aju IB Investment offers consulting services that focus on business management, tax, accounting, legal, mergers and acquisitions, additional funding, marketing, and technology support.Aju IB Investment was founded in September 1974 and is basedin Seoul, South Korea.

## Contacts

5 contacts available for Aju IB Investment. Shizune tracks 4 team members at Aju IB Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aju-ib-investment?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 38 | 24% |
| Health Care | 30 | 19% |
| Medical | 18 | 11% |
| Pharmaceutical | 16 | 10% |
| Therapeutics | 15 | 9% |

133 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 44 | 28% |
| Series B | 35 | 22% |
| Series C | 20 | 13% |
| Seed | 11 | 7% |
| Funding Round | 7 | 4% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 95 | 59% |
| United States | 15 | 9% |
| Japan | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Derek Yoon | Partner | 0 | https://shizune.co/investors/profile/derek-yoon |
| Jeong Moo-il | Team manager | 1 | https://shizune.co/investors/profile/jeong-moo-il |
| Jiwon Kim | CEO | 0 | https://shizune.co/investors/profile/jiwon-kim-405d |
| Yoon Chang-soo | General Manager | 1 | https://shizune.co/investors/profile/yoon-chang-soo |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FNCT Biotech | FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $14M | Series B | Jun 16, 2026 |  |
| Nventric | Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M | Venture - Series Unknown | Jun 10, 2026 |  |
| MangoBoost | Data Processing Unit (DPU) is a next-generation server accelerator designed to orchestrate various intra-server devices (e.g., CPU, GPU, SSD, NPU, NIC). By maximizing the datacenter’s overall performance and cost efficiency, DPU is now considered as the most important HW/SW solution to realize the next-generation extreme-scale AI serverinfrastructure. However, despite its critical necessity from the datacenter and AI infrastructure, there is no market-leading DPU solution which can meet the customer’s actual demand due to its HW/SW complexity and the application/model heterogeneity. MangoBoost is currently the world’s most highly recognized DPU startup located in US and Korea. We provide the world’s most advanced and flexible DPU HW/SW solutions in order to fully satisfy the needs of various customers. Our DPU HW is fully composable by integrating its rich set of DPU features to construct our customer-optimal DPUs. At the same time, our DPU SW enables to seamlessly deploy the solution to any customer environment. As a result, our DPU solutions are considered very promising to realize the next-generation AI/datacenter infrastructure, and thus they are currently evaluated at various global-leading companies. MangoBoost was founded in early 2022 to commercialize 7 year of top-tier DPU research outcomes achieved at Seoul National University (e.g., many full-system DPU prototypes, many ISCA/MICRO/ASPLOS/OSDI/ATC papers). The current team consists of 45+ system engineers including ~20 top-tier PhDs from Carnegie Mellon University, Seoul National University, POSTECH, U Toronto, and ~20 industry experts from Intel, Microsoft, Samsung, and Naver. | $6.7M | Series B | Apr 21, 2026 |  |
| PEOPLE & TECHNOLOGY | PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas. | $9.9M | Venture - Series Unknown | Apr 07, 2026 |  |
| Cenyx Biotech | Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles. | $8.2M | Series B | Mar 31, 2026 |  |
| Ark | Ark is an AI-based early screening company focused on identifying and preventing complications associated with chronic diseases, developing and supplying advanced medical AI solutions that enable early detection, risk assessment, and proactive disease management to support healthcare providers in delivering more precise and timely care. | $13.5M | Series A | Mar 05, 2026 |  |
| Pharos iBio Co. | Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases. | $12.9M | Post-IPO Debt | Dec 04, 2025 |  |
| Qymune | Qum Therapeutics Develops immunotherapies that target pathogenic cells. The company designs treatments to engage the patient’s immune system and control disease progression. Its approach focuses on precision targeting and minimizing side effects. The technology is applied to cancer and other diseases that involve pathogenic cells. | $10M | Seed | Nov 30, 2025 |  |
| Quantum AI | Quantum AI is an AI data company that offers offline and online data collection and analysis services. Currently, Quantum AI is providing various services centered on the financial sector, including AI document processing automation, intelligent voice consultation, assetization of unstructured financial data based on its own language model, and AIsearch. Utilizing a proprietary AI recognition engine, the company has integrated and analyzed various data sources, including financial documents, customer consultation history, and market news, and have carried out numerous AI data assetization projects for major domestic commercial banks and insurance companies. | $5M | Series B | Nov 06, 2025 |  |
| IMBiologics | IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M | Series C | Oct 14, 2025 |  |

10 of 160 investments shown.

## Co-investors
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 15 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 13 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 13 deals together
- [Shinhan Venture Investment](https://shizune.co/investors/profile/shinhan-venture-investment) — VC Fund, 13 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 12 deals together
- [NH Investment & Securities](https://shizune.co/investors/profile/nh-investment-securities) — VC Fund, 12 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [All Investors in South Korea](https://shizune.co/investors/investors-south-korea)
- [All VC Funds in South Korea](https://shizune.co/investors/vc-funds-south-korea)
- [SaaS Investors in South Korea](https://shizune.co/investors/saas-investors-south-korea)
- [SaaS VC Funds in South Korea](https://shizune.co/investors/saas-vc-funds-south-korea)
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)

## FAQ

### What does Aju IB Investment invest in?

Aju IB Investment invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 160 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aju IB Investment?

Public channels for Aju IB Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aju IB Investment?

The team at Aju IB Investment includes Derek Yoon (Partner), Jeong Moo-il (Team manager) and Jiwon Kim (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co